SCM
COGT icon

Sterling Capital Management’s Cogent Biosciences COGT Stock Holding History

Sterling Capital Management’s Portfolio COGT Stock Details COGT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$44.4K Sell
1,153
-165
-13% -$6.09K ﹤0.01% 1686
2025
Q4 		$46.8K Buy
1,318
+499
+61% +$14K ﹤0.01% 1830
2025
Q3 		$11.8K Buy
819
+466
+132% +$5.52K ﹤0.01% 2403
2025
Q2 		$2.54K Buy
353
+155
+78% +$859 ﹤0.01% 2853
2025
Q1 		$1.19K Sell
198
-107
-35% -$839 ﹤0.01% 2759
2024
Q4 		$2.38K Buy
305
+198
+185% +$1.97K ﹤0.01% 2736
2024
Q3 		$1.16K Buy
+107
New +$1.04K ﹤0.01% 2454

Other funds holding COGT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Sterling Capital Management's COGT Position: Q1 2026 in Review

Sterling Capital Management reduced its Cogent Biosciences (COGT) stake by 13% in Q1 2026, selling an estimated $6.09K and leaving 1,153 shares worth $44.4K. The position accounts for ﹤0.01% of the portfolio, ranked #1686.

Sterling Capital Management first reported a position in COGT in Q3 2024 and has held it in 7 quarters since. The position peaked at $46.8K in Q4 2025. 305 funds tracked by Wall St. Rank hold COGT as of Q1 2026.

  • Sterling Capital Management held 1,153 shares of Cogent Biosciences worth $44.4K as of Q1 2026.
  • Sterling Capital Management sold 165 Cogent Biosciences shares in Q1 2026, an estimated $6.09K.
  • Cogent Biosciences made up ﹤0.01% of Sterling Capital Management's portfolio in Q1 2026, its #1686 holding.
  • Sterling Capital Management first reported a position in Cogent Biosciences in Q3 2024 and has held it in 7 quarters since.
  • Sterling Capital Management's Cogent Biosciences position peaked at $46.8K in Q4 2025.
  • 305 funds tracked by Wall St. Rank held Cogent Biosciences as of Q1 2026.

Based on Sterling Capital Management's 13F filing for Q1 2026, filed 22 Apr 2026.